ライフサイエンスコーパス: enteric-coated

1 The belief that enteric-coated and buffered varieties are less likely to

2 (Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic

3 The relative risks of UGIB for plain, enteric-coated, and buffered aspirin at average daily do

4 Exposure of mice to enteric-coated antigen promotes an extensive T helper 2-

5 They received enteric-coated ASA after ulcer healing.

6 if still resistant were exposed to low-dose enteric coated aspirin (81 mg) and clopidogrel (75 mg) f

7 parent resistance to a single dose of 325-mg enteric coated aspirin (up to 49%) but not to immediate

8 gle oral dose of 325-mg immediate release or enteric coated aspirin.

9 lowing 7-day regimens in a crossover design: enteric-coated aspirin 100 mg twice daily, enteric-coate

10 : enteric-coated aspirin 100 mg twice daily, enteric-coated aspirin 200 mg once daily, or plain aspir

11 endoscopy were assigned randomly to placebo, enteric-coated aspirin 81 mg/day, rofecoxib 25 mg combin

12 dose had no association with effectiveness (enteric-coated aspirin AHR, 1.13; 95% CI, 0.88-1.45 and

13 , 0.83-1.18; interaction P = .41) or safety (enteric-coated aspirin AHR, 2.37; 95% CI, 1.02-5.50 and

14 7285 men [68.2%]), of whom 7366 (69.0%) took enteric-coated aspirin and 3312 (31.0%) took uncoated as

15 CI, 0.49-1.37; P = .46) outcomes between the enteric-coated aspirin and uncoated aspirin cohorts was

16 Within enteric-coated aspirin and uncoated aspirin, aspirin dos

17 in; there were insufficient data to evaluate enteric-coated aspirin at this dose level.

18 dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded.

19 (ASPREE) was undertaken comparing 100 mg of enteric-coated aspirin daily against matching placebo.

20 More research is needed to confirm whether enteric-coated aspirin formulations or newer formulation

21 A 100-mg daily dose of enteric-coated aspirin or matching placebo.

22 Daily 100-mg enteric-coated aspirin or matching placebo.

23 Clinicians recommend enteric-coated aspirin to decrease gastrointestinal blee

24 re ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release

25 d the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 m

26 of the ADAPTABLE randomized clinical trial, enteric-coated aspirin was not associated with significa

27 ized mice with oral allergen, in the form of enteric-coated beads, resulted in marked allergen-specif

28 yed and reduced drug absorption, complicates enteric coated but not immediate release aspirin adminis

29 wder of zwitterionic micelle insulin into an enteric-coated capsule.

30 Oral delivery of devices in enteric coated capsules resulted in significant bioavail

31 to produce a powder which was filled into 5 enteric-coated capsules (size 0).

32 irectly into the intestine of cats by use of enteric-coated capsules.

33 nd ritonavir for 7 days, (B) zidovudine plus enteric-coated didanosine for 30 days, or (C) regimen 1

34 and postpartum regimens: (A) zidovudine plus enteric-coated didanosine plus lopinavir and ritonavir f

35 phous solid-state form, and the integrity of enteric-coated drug delivery systems.

36 lipid-based aspirin), and a delayed-release enteric-coated (EC) aspirin.

37 We aimed to establish in vivo evidence that enteric-coated (EC) calcium is bioavailable in pregnant

38 duce the gastrointestinal effects of MMF, an enteric-coated formulation of the drug was developed, ba

39 n group received a daily dose of oral 100 mg enteric-coated (low-dose) aspirin.

40 ising single domain antibody formulated into enteric coated mini-tablets to enable release in the int

41 IL-11 was administered daily by enteric, coated multiparticle pellets over the course of

42 Conversion from SRL to enteric coated mycophenolate sodium led to an increase i

43 rospective trial with conversion from SRL to enteric coated mycophenolate sodium.

44 ity to absorb cyclosporin, tacrolimus (Tac), enteric-coated mycophenolate sodium (EC-MPS) and sirolim

45 mplaints from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) has not bee

46 nversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in terms of

47 nversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) significant

48 long-term outcomes of patients who received enteric-coated mycophenolate sodium (EC-MPS) versus myco

49 (GI) complications in patients treated with enteric-coated mycophenolate sodium (EC-MPS) versus myco

50 It was of interest to compare enteric-coated mycophenolate sodium (EC-MPS) versus myco

51 Although enteric-coated mycophenolate sodium (EC-MPS) was develop

52 nsisting of reduced tacrolimus dosing (rTd), enteric-coated mycophenolate sodium (EC-MPS), and early

53 In this study, the IEM was combined to enteric-coated mycophenolate sodium (ECMPS).

54 olate mofetil (group A, n=75) versus 1.440 g enteric-coated mycophenolate sodium (group B, n=75), wit

55 first long-term, randomized trial comparing enteric-coated mycophenolate sodium versus mycophenolate

56 l equivalents) was significantly higher with enteric-coated mycophenolate sodium versus mycophenolate

57 Use of low doses of enteric-coated or buffered aspirin carries a three-fold

58 nts was compared between participants taking enteric-coated or uncoated aspirin using unadjusted and

59 Once daily 100 mg aspirin (enteric coated) or placebo.

60 Aspirin (100 mg daily, enteric coated) or placebo.

61 approach to characterize the quality of the enteric-coated peptide product.

62 The control group received a daily identical enteric-coated placebo tablet.

63 ers ingested either a placebo or a partially enteric-coated preparation of bovine immunoglobulins wit

64 ) and an oral formulation of this API within enteric-coated sucrose spheres.

65 mal gastrointestinal absorption, targeted by enteric-coated tablets.

66 replication-deficient, orally administered, enteric-coated, vaccinia virus-vectored vaccine might sa

67 sis assessed the effectiveness and safety of enteric-coated vs uncoated aspirin among those participa

68 uggest platelet inhibition is decreased with enteric-coated vs uncoated aspirin formulations.